The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

BACKGROUND: The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine‐based therapy. This study aims to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales: Procaccio, Letizia, Merz, Valeria, Fasano, Morena, Vaccaro, Vanja, Giommoni, Elisa, Pretta, Andrea, Noventa, Silvia, Satolli, Maria Antonietta, Giordano, Guido, Zichi, Clizia, Pinto, Carmine, Zecchetto, Camilla, Barsotti, Giulia, De Vita, Ferdinando, Milella, Michele, Antonuzzo, Lorenzo, Scartozzi, Mario, Zaniboni, Alberto, Spadi, Rosella, Casalino, Simona, Bergamo, Francesca, De Toni, Chiara, Melisi, Davide, Lonardi, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358242/
https://www.ncbi.nlm.nih.gov/pubmed/37278395
http://dx.doi.org/10.1002/cam4.6111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358242/
https://www.ncbi.nlm.nih.gov/pubmed/37278395
http://dx.doi.org/10.1002/cam4.6111

Ejemplares similares